Saltar al contenido
República del Perú · Observatorio de la producción científica universitaria
OApol.org Observatorio de Inteligencia Científica Universitaria del Perú
OApol.org
Inicio Universidades Publicaciones Investigadores
Repositorios
Tesis y trabajos académicosRevistas
Indicadores
Ranking trimestralRanking por carreraObjetivos de Desarrollo SostenibleReporte OCDERed neuronal 3D
Acerca
MetodologíaPrivacidad

Ranibizumab for the treatment of retinopathy of prematurity: systematic review and meta-analysis

Alva N.; Martínez A.R.; Ortiz-Saavedra B.; Montes-Madariaga E.S.; Cotrina A.; Caballero-Alvarado J.A.; Sah R.; Barboza J.J. · Frontiers in Pediatrics (2023) · DOI: 10.3389/fped.2023.1202927

Resumen

Anti-VEGF drugs like ranibizumab can be used to treat retinopathy of prematurity (ROP) by halting the formation of abnormal blood vessels, or lasers can be used to burn the edges of the retina where these vessels are present. The objective is to compare the efficacy for ROP between ranibizumab and laser therapy. Material and methods: Electronic searches will be carried out in medical databases with key words and controlled vocabulary terms. Randomized controlled trials (RCT) will be assessed. The primary outcome will be the full ROP regression. Two reviewers will extract the data using predefined forms and, to assess the quality of the study, we will use RoB 2.0, the tool for randomized controlled trials developed by the Cochrane Collaboration. We used a combination of the inverse-variance approach and random-effects models for the meta-analysis. Results: The eyes of 182 preterm infants who had ranibizumab treatment were assessed in a total of 364 eyes, and 135 infants received laser therapy. The follow-up period was between 6 and 24 months. Ranibizumab was not associated with greater regression of ROP compared to laser therapy in preterm infants (RR: 1.09, CI 95%: 0.95–1.24; p: 0.22). Also, ranibizumab was not associated with recurrence of ROP compared to laser therapy in preterm infants (RR: 3.77, CI 95%: 0.55–25.81; p: 0.22). Conclusions: The efficacy of ranibizumab compared to laser is very uncertain in terms of ROP regression and decreased ROP recurrence in preterm infants. Systematic Review Registration: identifier PROSPERO (CRD42022324150). 2023 Alva, Martínez, Ortiz-Saavedra, Montes-Madariaga, Cotrina, Caballero-Alvarado, Sah and Barboza.

Instituciones: Universidad Peruana Cayetano Heredia; Universidad Peruana de Ciencias Aplicadas; Universidad Nacional de San Agustín de Arequipa; Universidad Privada Antenor Orrego; Universidad César Vallejo